timothy sykes logo
Capricor Therapeutics Soars As Deramiocel Bet Draws Big Upgrades Thumbnail
G Google News

Capricor Therapeutics Soars As Deramiocel Bet Draws Big Upgrades

BRYCE TUOHEY•UPDATED AUG. 26, 2026, 12:33 PM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Capricor Therapeutics Inc. jumped as stocks have been trading up by 10.37 percent following highly positive clinical trial news

Key Takeaways Traders Need To Know

  • Cantor hiked its CAPR rating to Overweight and lifted its price target to $28 from $3.50 after Q2 earnings and fresh FDA engagement on deramiocel.
  • Oppenheimer followed with an Outperform on CAPR and a $54 price target after a favorable FDA-related update, signaling rising confidence in deramiocel’s approval odds.
  • Shares of Capricor Therapeutics have ripped higher multiple times, spiking roughly 83%–104% around Q2 results, FDA review news, and analyst upgrades.
  • The FDA pushed the deramiocel PDUFA date out three months to 2026/11/22 to review new Phase 3 data, delaying a final call but keeping the door open.
  • Capricor reported Q2 2026 with no revenue, a larger loss, and about $238M in cash, as it focuses almost entirely on its Duchenne muscular dystrophy cell therapy.

Candlestick Chart

Live Update At 12:32:32 EDT: On Wednesday, August 26, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending up by 10.37%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CAPR has turned into a classic event‑driven biotech trade. The company behind Capricor Therapeutics is still pre‑revenue, burning cash while it waits on the FDA. In Q2 2026, CAPR posted a net loss of about $40.7M and negative operating cash flow of roughly $31.5M, showing how much it spends to push deramiocel toward the finish line.

The flip side is the balance sheet. Capricor Therapeutics reported about $238M in cash, cash equivalents, and short‑term investments, plus working capital of more than $200M. With a current ratio of 7.4, CAPR is not about to run out of money tomorrow, even as free cash flow ran around -$35.5M for the quarter.

More Breaking News

On the chart, CAPR has shifted from sleepy to explosive. The stock closed at $4.21 just weeks ago and recently finished at $9.15 after hitting $9.88 intraday. That’s more than a double in a short window. Intraday 5‑minute candles show steady premarket grinding around $8.20–$8.30, then a strong push through $9 and a controlled consolidation in the low $9s. For traders, that blend of momentum and tight intraday ranges screams “watch list,” especially into the next FDA headline.

Why Traders Are Locked In On CAPR Now

Capricor Therapeutics has moved from obscure biotech to front‑page ticker on many scanners. The spark was regulatory. After a harsh 9‑3 negative advisory committee vote on deramiocel’s original cardiomyopathy indication, most traders wrote CAPR off as another biotech casualty. Then the FDA signaled it would review a major amendment to the biologics license application, shifting the focus to upper‑limb skeletal muscle function in Duchenne muscular dystrophy and pulling in fresh 24‑month HOPE‑3 data.

That single change flipped sentiment. CAPR shares have surged repeatedly — over 85% on one FDA review headline and roughly 104% in premarket after Q2 numbers hit and the market liked what it saw. Another spike of about 83% came as the deramiocel narrative improved and Cantor’s upgrade landed, pushing Capricor Therapeutics toward the $7–$8 zone and beyond.

Wall Street is now leaning in. Cantor Fitzgerald raised its CAPR rating to Overweight and slammed its target up to $28 from $3.50. Oppenheimer went even further with a $54 target after the latest FDA‑related update. When two major firms project many multiples of upside, momentum traders listen. But the catch is clear: all of this bullishness hangs on deramiocel getting across the regulatory finish line.

The extended PDUFA date to 2026/11/22 cuts both ways. CAPR gets more time and a real shot with new data, yet traders must now sit through months of headline risk, profit‑taking, and shakeouts. Overlay that with activist noise from Kaos Capital pushing Capricor Therapeutics toward strategic alternatives, board refresh, and M&A exploration, and you have a powder‑keg setup. CAPR is no slow‑and‑steady story; it’s a binary catalyst play with a thick layer of governance drama.

Conclusion

For active traders, CAPR is a live case study in how news, charts, and psychology collide. Capricor Therapeutics is still losing money, still pre‑revenue, and still tied almost entirely to one asset. Return on equity is deeply negative, and pretax margins are ugly. But the company has meaningful cash, modest leverage, and an FDA that has not shut the door on deramiocel. Instead, regulators are reviewing more HOPE‑3 data and considering a narrower indication that already hit its primary endpoint and landed in The Lancet.

That backdrop explains why CAPR has morphed into a momentum vehicle. Every fresh FDA headline, every analyst move from Cantor or Oppenheimer, and every activist letter from Kaos Capital becomes a trading catalyst. When the stock grinds premarket, then rips on volume through $9, disciplined traders know to plan entries, exits, and risk levels before emotion takes over.

Tim Sykes often tells students, “The market rewards prepared traders, not hopeful gamblers.” As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. CAPR is exactly the kind of story where that mindset matters. Study the deramiocel timeline, map the 2026/11/22 PDUFA date, track Capricor Therapeutics price action, and always remember this is for education and research only — not a signal to buy or sell.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”